Apellis Eye Injection Treatment Flagged for Safety Issues 7/31/2023

Early-Stage Biopharma Funding to Drop 40% This Year: Report 7/31/2023

House Republicans Propose Drug Shortage Legislation After Gutting Democrats’ Bill 7/31/2023

Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space 7/31/2023

FDA Action Alert: Mesoblast, Sage/Biogen and Galera 7/31/2023

Sana Biotechnology Advances R&D Platform to Overcome Immune Rejection 7/31/2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells - which play a key role in immune response - that eradicated tumors and prevented their recurrence in mouse models of melanoma.

The findings, which suggest that the approach has the potential to be effective against tumors that have already spread to other parts of the body and against different cancer types,

Week in Review: Biogen M&A and Layoffs, Earnings Season Heats Up, and 12 Neuro Companies to Watch 7/28/2023

Biogen Boosts Neuro Pipeline with $7.3B Reata Buy Amid Layoffs 7/28/2023

AstraZeneca, Pfizer Ink Potential $1B Gene Therapy Deal 7/28/2023

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year 7/28/2023

Merck’s Pneumococcal Shot Claims Back-to-Back Phase III Wins 7/28/2023

Takeda Likely to Drop Rare Genetic Disease Candidate After Phase II Fail 7/28/2023

Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.

Effective today, Chris Boshoff, M.D., PhD, will join Pfizer's Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to

Lilly’s Tirzepatide Cuts Weight of Enrollees by 26% in Phase III Trials 7/27/2023

BMS Reports Q2 Sales Miss Amid Generic Competition, Lowers Full-Year Guidance 7/27/2023

Roche Drops Hemophilia A Candidate, Prepares for the Impacts of IRA 7/27/2023

Alkermes Gets $248M Boost from J&J, Gives Bullish Outlook on Teva Legal Fight 7/27/2023

Sage Stock Drops Despite Promising Phase III Depression Data 7/27/2023

Opinion: The Power of Credibility—How Emerging Biotechs Can Earn Candidates’ Trust 7/27/2023